Iterative Health's Site Network Model Boosts Clinical Trial Execution

ECCO 2026 data validates Iterative Health's approach to accelerate enrollment and shorten timelines for inflammatory bowel disease trials.

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

Iterative Health, a healthcare technology and services company, announced the publication of scientific research at the 21st Congress of European Crohn's and Colitis Organisation (ECCO) in 2026. The research highlights the performance metrics of Iterative Health's global research network, demonstrating the impact of their site-centric partnership model in improving trial execution and bringing novel therapies to patients faster.

Why it matters

The study found that Iterative Health's approach helped sites enroll patients at an average rate 3.4 times higher than industry benchmarks, and reduced activation timelines by 3 months, without compromising quality. This suggests that Iterative Health's model can help address longstanding challenges in clinical research related to trial delays and lagging enrollment rates.

The details

The study, titled 'Accelerating enrollment in phase 2 and 3 inflammatory bowel disease trials through an innovative site network,' evaluated performance across several ulcerative colitis and Crohn's disease randomized controlled trials conducted across the United States and Europe. Iterative Health's site network is empowered with operational infrastructure, standardized processes, study-specific training, and AI-powered technology designed to drive trial success and sustainability.

  • The ECCO 2026 Congress took place from February 18-21, 2026 in Stockholm, Sweden.
  • The research was published at the ECCO 2026 Congress.

The players

Iterative Health

A healthcare technology and services company powering the acceleration of clinical research to transform patient outcomes.

Laurent Peyrin-Biroulet, MD, PhD

Lead study author and professor of gastroenterology.

J. Casey Chapman, MD

Study author and Chief Medical Officer of GI Alliance.

Dana Feuchtbaum

Chief Operating Officer of Iterative Health.

Got photos? Submit your photos here. ›

What they’re saying

“The research investigated an innovative approach to longstanding challenges in clinical research related to trial delays and lagging enrollment rates across sites. With per-site randomization rates falling by more than 70% over the last decade in ulcerative colitis and Crohn's disease, the consistency and scale of performance observed by the Iterative Health site network points to a more sustainable way to drive the development of novel therapies for patients.”

— Laurent Peyrin-Biroulet, MD, PhD, Lead study author and professor of gastroenterology

“From a U.S. site perspective, the trial performance reflected in this data is particularly meaningful. When a purpose-built clinical research infrastructure focuses on high-performing, sustainable, community-based research sites, it becomes possible to set a higher standard for enrollment and speed. Trials can move forward more efficiently, expanding access to treatment options and ultimately advancing patient care.”

— J. Casey Chapman, MD, Study author and Chief Medical Officer of GI Alliance

“This publication marks the first time Iterative Health has reported aggregated performance metrics and reflects our promise of data-driven and impactful innovation. The results demonstrate a business model that is intentionally designed to accelerate clinical research, paving the way to expand across GI, hepatology, and additional therapeutic areas.”

— Dana Feuchtbaum, Chief Operating Officer of Iterative Health

What’s next

Iterative Health plans to expand its site network model to additional therapeutic areas beyond inflammatory bowel disease, such as gastroenterology and hepatology.

The takeaway

Iterative Health's innovative approach to clinical trial execution, with a focus on empowering high-performing, sustainable research sites, has demonstrated the potential to significantly improve enrollment rates and shorten timelines without compromising quality, paving the way for faster development of novel therapies for patients.